Glucagon-like peptide-1 receptor agonists are associated with decreased risk of progression from non-proliferative diabetic retinopathy to vision threatening diabetic retinopathy

被引：0
|
作者：
Tauqeer, Zujaja [1 ]
Bracha, Peter [1 ,2 ]
Hua, Peiying [3 ]
Cui, Qi N. [1 ]
VanderBeek, Brian L. [1 ,4 ]
机构：
[1] Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA USA
[2] Gundersen Hlth Syst, Gundersen Eye Inst, La Crosse, WI USA
[3] Univ Penn, Perelman Sch Med, Ctr Preventat Ophthalmol & Biostat, Philadelphia, PA 19104 USA
[4] Univ Penn, Perelman Sch Med, Ctr Pharmacoepidemiol Res & Training, Philadelphia, PA 19104 USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2021年 / 62卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy
    Roshan Dhanapalaratnam
    Tushar Issar
    Alexandra T. K. Lee
    Ann M. Poynten
    Kerry-Lee Milner
    Natalie C. G. Kwai
    Arun V. Krishnan
    Diabetologia, 2024, 67 : 561 - 566
  • [42] Characterization of real-world progression from non-proliferative to proliferative diabetic retinopathy in patients with diabetes
    Babiuch, Amy
    Gale, Sara L.
    Conti, Thais F.
    McLaughlin, Lucas
    Kalur, Aneesha
    Gan, Ryan
    Iyer, Amogh
    Ferrara, Daniela
    Greenlee, Tyler
    Spicer, Galin Jackson
    Muste, Justin
    Hopkins, Jill Jill
    Singh, Rishi P.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [43] Fenofibrate and Statin Use and the Risk of Progression to Vision Threatening Diabetic Retinopathy
    VanderBeek, Brian L.
    Bavinger, J. Clay
    Yu, Yinxi
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [44] Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy
    Dhanapalaratnam, Roshan
    Issar, Tushar
    Lee, Alexandra T. K.
    Poynten, Ann M.
    Milner, Kerry-Lee
    Kwai, Natalie C. G.
    Krishnan, Arun V.
    DIABETOLOGIA, 2024, 67 (03) : 405 - 406
  • [45] Comprehensive review of glucagon-like peptide receptor agonist treatment on the risk of cardiovascular outcomes and retinopathy as diabetic complications
    Liu, H.
    Zhang, J. -T.
    Xin, S. -H.
    Ren, W. -N.
    Lu, Q. -K.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (06) : 2332 - 2340
  • [46] The Effect of Glucagon-like-Peptide-1 Receptor Agonists on Diabetic Retinopathy Progression, Central Subfield Thickness, and Response to Intravitreal Injections
    Michaeli, Tomer
    Khateb, Samer
    Levy, Jaime
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (20)
  • [47] Metformin effects on glucagon-like peptide-1 levels in obese diabetic and non diabetic patients
    Mannucci, E
    Bardini, G
    Tesi, F
    Ognibene, A
    Petracca, MG
    Ciani, S
    Brogi, M
    Cremasco, F
    Messeri, G
    Rotella, CM
    DIABETOLOGIA, 2002, 45 : A217 - A217
  • [48] Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis
    Yoshida, Yilin
    Joshi, Preeti
    Barri, Saba
    Wang, Jia
    Corder, Amy L.
    O'Connell, Samantha S.
    Fonseca, Vivian A.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2022, 36 (08)
  • [49] Gastric ultrasound and mitigating risk of glucagon-like peptide-1 receptor agonists
    Hurley, Cian
    Kearsley, Rosemarie
    ANAESTHESIA, 2024, 79 (10) : 1131 - 1132
  • [50] Glucagon-like Peptide-1 Receptor Agonists Reduce The Risk Of Ischemic Stroke
    Goldstein, Eric
    Garg, Gauri
    Navarro, Kayla
    Wong, Ka-ho
    de Havenon, Adam H.
    STROKE, 2022, 53
12345